ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för deferiprone. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

23 träffar

Bibliografisk träff 2013-01-01

Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.

Kolnagou A, Natsiopoulos K, Kleanthous M, Ioannou A, Kontoghiorghes GJ.

Toxicol Mech Methods · journal article · DOI 10.3109/15376516.2012.727198

Bibliografisk träff 2012-10-24

Effect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease.

Rajapurkar MM, Hegde U, Bhattacharya A, Alam MG, Shah SV.

Toxicol Mech Methods · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.3109/15376516.2012.730558

Bibliografisk träff 2012-07-30

Antibacterial activities of iron chelators against common nosocomial pathogens.

Thompson MG, Corey BW, Si Y, Craft DW, Zurawski DV.

Antimicrob Agents Chemother · brief-report; journal article · DOI 10.1128/aac.01197-12

Bibliografisk träff 2012-07-02

Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients.

Rodrat S, Yamanont P, Tankanitlert J, Chantraraksri U, Fucharoen S, Morales NP.

Pharmacology · comparative study; clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1159/000339658

Bibliografisk träff 2012-05-24

Wound healing by topical application of antioxidant iron chelators: kojic acid and deferiprone.

Mohammadpour M, Behjati M, Sadeghi A, Fassihi A.

Int Wound J · comparative study; research-article; journal article · DOI 10.1111/j.1742-481x.2012.00971.x

Bibliografisk träff 2012-05-24

Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients.

Maggio A, Vitrano A, Lucania G, Capra M, Cuccia L, Gagliardotto F, Pitrolo L, Prossomariti L, Filosa A, Caruso V, Gerardi C, Campisi S, Cianciulli P, Rizzo M, D'Ascola G, Ciancio A, Di Maggio R, Calvaruso G, Pantalone GR, Rigano P.

Am J Hematol · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1002/ajh.23219

Bibliografisk träff 2012-05-10

Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.

Cassinerio E, Roghi A, Pedrotti P, Brevi F, Zanaboni L, Graziadei G, Pattoneri P, Milazzo A, Cappellini MD.

Ann Hematol · comparative study; clinical trial; journal article · DOI 10.1007/s00277-012-1480-8

Bibliografisk träff 2012-05-05

Iron mobilization using chelation and phlebotomy.

Flaten TP, Aaseth J, Andersen O, Kontoghiorghes GJ.

J Trace Elem Med Biol · review; journal article · DOI 10.1016/j.jtemb.2012.03.009

Bibliografisk träff 2012-05-01

Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina.

Song D, Song Y, Hadziahmetovic M, Zhong Y, Dunaief JL.

Free Radic Biol Med · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.freeradbiomed.2012.04.020

Bibliografisk träff 2012-05-01

The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.

Mirbehbahani N, Jahazi A, Rahim Abad HH.

Hematology · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1179/102453312x13376952196610

Bibliografisk träff 2012-04-02

Ferric complexes of 3-hydroxy-4-pyridinones characterized by density functional theory and Raman and UV-vis spectroscopies.

Šebestík J, Safařík M, Bouř P.

Inorg Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/ic202004d

Bibliografisk träff 2012-04-01

Quantitative determination of deferiprone in human plasma by reverse phase high performance liquid chromatography and its application to pharmacokinetic study.

Abbas M, Nawaz R, Iqbal T, Alim M, Asi MR.

Pak J Pharm Sci · research support, non-u.s. gov't; journal article

Bibliografisk träff 2012-03-27

Development of a fast LC-MS/MS assay for the determination of deferiprone in human plasma and application to pharmacokinetics.

Song TS, Hsieh YW, Peng CT, Liu CH, Chen TL, Hour MJ.

Biomed Chromatogr · journal article · DOI 10.1002/bmc.2734

Bibliografisk träff 2012-03-01

Thalassemia Major in Adults: Short Stature, Hyperpigmentation, Inadequate Chelation, and Transfusion-Transmitted Infections are Key Features.

Prakash A, Aggarwal R.

N Am J Med Sci · research-article; journal article · DOI 10.4103/1947-2714.93886

Bibliografisk träff 2012-02-01

Deferiprone (Ferriprox) for iron overload.

Författaruppgift saknas

Med Lett Drugs Ther · review; journal article

Bibliografisk träff 2012-01-25

Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.

Alpendurada F, Smith GC, Carpenter JP, Nair SV, Tanner MA, Banya W, Dessi C, Galanello R, Walker JM, Pennell DJ.

J Cardiovasc Magn Reson · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1532-429x-14-8

Bibliografisk träff 2012-01-01

Use of deferiprone for the treatment of hepatic iron storage disease in three hornbills.

Sandmeier P, Clauss M, Donati OF, Chiers K, Kienzle E, Hatt JM.

J Am Vet Med Assoc · research support, non-u.s. gov't; journal article; case reports · DOI 10.2460/javma.240.1.75

Bibliografisk träff 2012-01-01

Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet.

Prasanthi JR, Schrag M, Dasari B, Marwarha G, Dickson A, Kirsch WM, Ghribi O.

J Alzheimers Dis · research-article; journal article; research support, n.i.h., extramural · DOI 10.3233/jad-2012-111346

Bibliografisk träff 2011-12-16

Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.

Aydinok Y, Evans P, Manz CY, Porter JB.

Haematologica · clinical trial; research-article; journal article · DOI 10.3324/haematol.2011.056317

Bibliografisk träff 2011-11-30

Synthesis, physicochemical properties and antioxidant activity of deferiprone-cyclodextrin conjugates and their iron(III) complexes.

Puglisi A, Spencer J, Oliveri V, Vecchio G, Kong X, Clarke J, Milton J.

Dalton Trans · research support, non-u.s. gov't; journal article · DOI 10.1039/c1dt11677k

Bibliografisk träff 2011-10-27

Pilot safety trial of deferiprone in 10 subjects with superficial siderosis.

Levy M, Llinas R.

Stroke · research support, non-u.s. gov't; journal article · DOI 10.1161/strokeaha.111.628032

Bibliografisk träff 2011-10-24

Chelation of aluminum by combining deferasirox and deferiprone in rats.

Saljooghi AS.

Toxicol Ind Health · journal article · DOI 10.1177/0748233711422731

Bibliografisk träff 2011-08-18

Determination of deferiprone in urine and serum using a terbium-sensitized luminescence method.

Manzoori JL, Amjadi M, Soleymani J, Tamizi E, Rezamand A, Jouyban A.

Luminescence · research support, non-u.s. gov't; evaluation study; journal article · DOI 10.1002/bio.1344